MarketMoodz
UBS urges contrarian buy of Perimeter Solutions as fire-safety stock sinks
UBS upgraded Perimeter Solutions (PRM) to Buy from Neutral and lifted its price target to $30 from $26, arguing the pullback creates a contrarian buying opportunity. The stock is down roughly 22%-23% year-to-date, but UBS sees upside from a backlog buildup, the Medical Manufacturing Technologies acquisition, and improving demand for fire-safety gear.
Key Takeaways
- UBS raises PRM target to $30 and upgrades to Buy from Neutral
- PRM down >22%-23% YTD, yet up ~11% over the last 12 months
- Selloff linked to a high-water mark for executive compensation near $28 per share
- Acquisition of Medical Manufacturing Technologies completed, expanding output and services for PRM (~$700 million)
- UBS projects 2026 EBITDA of ~5% and 2027 ~9%, with a high-margin profile supporting cash flow
People Involved
- UBS Equity Research Team Analysts covering Perimeter Solutions
Entities Involved
- Perimeter Solutions (PRM) Fire-safety and fire-retardant products manufacturer
- Medical Manufacturing Technologies Acquired by Perimeter Solutions for about $700 million; expands output and services
- UBS Group AG Investment bank issuing upgrade on PRM
MarketMoodz Analysis
The buy rating and $30 target introduce a contrarian catalyst for a stock that’s been punished in 2026. UBS argues the selloff is overdone given PRM’s high-margin/low-capex profile, roughly 50% aftermarket revenue, and improving demand for fire-safety products. If backlog growth and the Services expansion from the Medical Manufacturing Technologies deal materialize, the company could see multiple expansion even as the broader headwinds persist.
UBS also frames CEO-level payout dynamics as a near-term risk, noting the high-water mark for executive compensation sits near $28 per share. That dynamic underpins a potential ~30% upside baked into the target but underscores the need to verify payout details and ensure dilution is manageable. Historically, defensive industrial names with steady cash flow have offered ballast in a high-rate environment, and PRM’s mix of backlog, acquisitions, and end-market safety demand could support a resilient cash flow trajectory.
What to watch next: monitor backlog trajectory and end-market safety spending into 2026-27, track regulatory-driven purchases, and verify the accuracy of payout and acquisition details (8-K filings, UBS note). The two-analyst coverage (one Hold, one Buy) could recalibrate as new data arrives, shaping whether PRM compounds its upside or remains a volatility-sensitive play.
Source: Original Article
Get AI-Powered Market Insights
Stay ahead of market-moving events with our real-time analysis and stock ratings.
Start Your Free Trial